Stay updated on SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial

Sign up to get notified when there's something new on the SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for the SBRT and nivolumab/ipilimumab kidney cancer study, including its study details, eligibility criteria, locations, and results information, instead of an access-denied error.
    Difference
    50%
    Check dated 2026-11-10T10:18:55.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The site’s displayed revision changed from v3.7.2 to v3.8.0; the page still shows a 403 error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-03T10:49:44.000Z thumbnail image
  3. Check
    27 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-20T11:21:34.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T10:18:16.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, indicating access to the study record is blocked. The standard site chrome remains visible, but the actual content is inaccessible, signaling a access restriction rather than a change to the study information.
    Difference
    19%
    Check dated 2026-09-22T12:24:54.000Z thumbnail image
  6. Check
    77 days ago
    Change Detected
    Summary
    Revision label updated from v3.6.5 to v3.6.6. This indicates a minor platform/update change and does not modify study content.
    Difference
    0.1%
    Check dated 2026-08-31T23:58:53.000Z thumbnail image

Stay in the know with updates to SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial page.